Lina M. Alneghery

The era of biogenic nanoparticles (BNPs) marks a transformative period in nanotechnology, leveraging plants, bacteria, and fungi to synthesize nanoparticles. This green approach offers significant advantages, including enhanced biocompatibility, sustainability, and a wide range of diverse applications. The introduction of BNPs into ecosystems and their interactions with biological systems pose potential risks that demand rigorous testing and stringent regulatory oversight. Furthermore, in medical applications, the principle of informed consent is paramount, ensuring that patients are fully informed about the benefits and potential risks of BNP-based treatments. Environmental pollution and its impact is another critical area of concern. While BNPs are often promoted as environmentally friendly alternatives, their long-term effects on ecosystems remain insufficiently understood. The rapid advancement and integration of BNPs across sectors necessitate a comprehensive examination of the ethical and societal considerations to mitigate unforeseen consequences. From a societal perspective, it is crucial to ensure that the benefits of BNPs are universally accessible. Effective communication strategies are vital for establishing public trust and dispelling misconceptions, thereby promoting an informed and supportive societal response. Adaptive regulatory frameworks tailored to the unique challenges of BNPs are a must to ensure the responsible and sustainable benefits of BNPs.

The Marburg virus (MBV), a deadly pathogen, poses a serious threat to world health due to the lack of effective treatments, calling for an immediate search for targeted and efficient treatments. In this study, we focused on compounds originating from marine fungi in order to identify possible inhibitory compounds against the Marburg virus (MBV) VP35-RNA binding domain (VP35-RBD) using a computational approach. We started with a virtual screening procedure using the Lipinski filter as a guide. Based on their docking scores, 42 potential candidates were found. Four of these compounds—CMNPD17596, CMNPD22144, CMNPD25994, and CMNPD17598—as well as myricetin, the control compound, were chosen for re-docking analysis. Re-docking revealed that these particular compounds had a higher affinity for MBV VP35-RBD in comparison to the control. Analyzing the chemical interactions revealed unique binding properties for every compound, identified by a range of Pi–cation interactions and hydrogen bond types. We were able to learn more about the dynamic behaviors and stability of the protein–ligand complexes through a 200-nanosecond molecular dynamics simulation, as demonstrated by the compounds’ consistent RMSD and RMSF values. The multidimensional nature of the data was clarified by the application of principal component analysis, which suggested stable conformations in the complexes with little modification. Further insight into the energy profiles and stability states of these complexes was also obtained by an examination of the free energy landscape. Our findings underscore the effectiveness of computational strategies in identifying and analyzing potential inhibitors for MBV VP35-RBD, offering promising paths for further experimental investigations and possible therapeutic development against the MBV.

Insulin resistance is a complex metabolic characteristic that increases the risk of developing cardiovascular disease which results from hypertension and dyslipidemia. The interaction of hereditary and environmental are factors driving the emergence of such disorders. Molecular techniques have now enabled the discovery of uncommon variations linked to the etiology of these disorders. Lipid metabolism is connected to various genetic variations associated with the etiology of metabolic syndrome. There are several genetic variants including epigenetic modifications alongside immunological status interference with pathogenic infectious that are directly related to insulin resistance and glucose metabolism. However, functional studies are required to determine the role of various genetic variations and other distinct factors in the development of insulin resistance. This review aims to give a broad overview of the interference of these genetic variants in the occurrence of insulin resistance. We also provide a summary of current developments in the environmental and immune factors associated with type 2 diabetes.

The lumpy skin disease virus (LSDV) infects cattle and buffalo and causes lumpy skin disease (LSD). It affects the lymph nodes of the sick animals, causing them to enlarge and appear as lumps (cutaneous nodules) that are 2–5 cm in diameter on their heads, necks, limbs, udders, genitalia, and perinea. A high temperature, a sharp drop in milk supply, discharge from the eyes and nose, salivation, a loss of appetite, depression, damaged hides, and emaciation are further warning signs and symptoms. As per the Food and Agriculture Organization (FAO), the incubation period, or the time between an infection and symptoms, is approximately 28 days. Infected animals can transfer the virus by direct contact with the vectors, direct virus secretion from mouth or nose, shared feeding and watering troughs, and even artificial insemination. The World Organization for Animal Health (WOAH) and the FAO both warn that the spread of illnesses could lead to serious economic losses. This illness reduces cow’s milk production because oral ulcers make the animal weak and lead them to lose their appetite. There are many diagnostics available for LSDV. However, very few tests yield accurate findings. The best methods for preventing and controlling the lumpy skin condition include vaccination and movement restrictions. As a specific cure is not available, the only available treatment for this illness is supportive care for cattle. Recently, India has developed a homologous, live-attenuated vaccine, Lumpi-ProVacInd, which is specifically intended to protect animals against the LSD virus. This study’s primary goal is to accumulate data on symptoms, the most accurate method of diagnosis, treatments, and controls to stop infections from spreading as well as to explore future possibilities for the management of LSDV.

Cardiovascular disease is the primary reason for chronic heart diseases and mortality worldwide. Hypertension (HTN) is the utmost dominant risk factor for the evolution of several diseases. Herbal medicines, traditional medicinal herbs, and their extracts are widely utilized to treat and monitor HTN. Herbal components have been shown to help relax arteries and lower oxidative stress. The current study assesses the probable role of herbal plant extract Lagerstroemia speciosa (LS) in the LNAME induced HTN in rats. LNAME (50 mg/100 mL) in drinkable water was given to rats for five weeks. There was a significant upsurge in LNAME‐treated hypertensive rats’ blood pressure (BP). On treatment with LS, it ameliorates blood pressure. Further, LS also improved body weight, reduced heart weight, and heart hypertrophy. The NO/cGMP concentration was lowered along with a substantial upsurge in the level of glutathione and a decline in MDA level. The LS extract also reduced the inflammatory cytokine markers in the systemic circulation. In conclusion, thus, the extract of LS treatment can efficiently alleviate the BP, oxidative stress markers, and inflammation and improve NO/cGMP concentration in LNAME induced HTN in rats.